Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 21, 2011, Pages 8773-8778

  Shaw, Alice T ^a,b   Winslow, Monte M ^a   Magendantz, Margaret ^a   Ouyang, Chensi ^a   Dowdle, James ^a   Subramanian, Aravind ^c   Lewis, Timothy A ^c   Maglathin, Rebecca L ^c   Tolliday, Nicola ^c   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Synthetic lethality; Targeted therapy

Indexed keywords

K RAS PROTEIN; LANPERISONE; TOLPERISONE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL KILLING; EMBRYO; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; MICE; NEOPLASMS; OXIDATIVE STRESS; RAS PROTEINS; REACTIVE OXYGEN SPECIES;

MUS;

EID: 79957722003     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105941108     Document Type: Article

References (33)

1. Mascaux C, et al. (2005) The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139. (Pubitemid 40188446)
2. Cengel KA, et al. (2007) Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9:341-348. (Pubitemid 46608301)
3. Winton T, et al.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597.
4. Pao W, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17.
5. Massarelli E, et al. (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896. (Pubitemid 46849563)
6. Van Cutsem E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417.
7. Ji H, et al. (2007) Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939. (Pubitemid 46910201)
8. Rinehart J, et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462. (Pubitemid 41185111)
9. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant KrasG12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
10. Kohl NE, et al. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797.
11. Adjei AA, et al. (2003) Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760-1766. (Pubitemid 46638589)
12. Macdonald JS, et al. (2005) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Invest New Drugs 23:485-487. (Pubitemid 41160096)
13. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19: 940-945. (Pubitemid 32947572)
14. Dolma S, Lessnick SL, Hahn WC, Stockwell BR (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3:285-296. (Pubitemid 37443883)
15. Guo W, Wu S, Liu J, Fang B (2008) Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 68:7403-7408.
16. Yagoda N, et al. (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447:864-868. (Pubitemid 46920135)
17. Barbie DA, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112.
18. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848.
19. Scholl C, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834.
20. Sakitama K, Ozawa Y, Aoto N, Tomita H, Ishikawa M (1997) Effects of a new centrally acting muscle relaxant, NK433 (lanperisone hydrochloride) on spinal reflexes. Eur J Pharmacol 337:175-187. (Pubitemid 27507781)
21. Tuveson DA, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375-387. (Pubitemid 38482073)
22. Shaw AT, et al. (2007) Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21:694-707. (Pubitemid 46440291)
23. Lamb J, et al. (2006) The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935. (Pubitemid 44497995)
24. Hieronymus H, et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330. (Pubitemid 44512193)
25. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550. (Pubitemid 41528093)
26. Yang WS, Stockwell BR (2008) Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 15:234-245. (Pubitemid 351391983)
27. Kocsis P, et al. (2005) Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther 315:1237-1246. (Pubitemid 41635412)
28. Douer D, Tallman MS (2005) Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396-2410. (Pubitemid 46218734)
29. Chou WC, et al. (2004) Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 101:4578-4583.
30. Trachootham D, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241-252. (Pubitemid 44311067)
31. Weinberg F, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788-8793.
32. Skinner J, et al. (2004) Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: Implications for models of human tumorigenesis. Oncogene 23:5994-5999. (Pubitemid 39093544)
33. Koeller KM, et al. (2003) Chemical genetic modifier screens: Small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol 10:397-410. (Pubitemid 36599248)